A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00354562. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT00354562
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Not listed
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Jan 31, 2008
- Completion
- Not listed
- Last update posted
- Jan 6, 2011
Started 2007
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Ref # / Investigator 3572 | Birmingham | Alabama | 35294-3300 | — |
| Site Ref # / Investigator 4771 | Burbank | California | 91505 | — |
| Site Ref # / Investigator 3574 | Orange | California | 92868-3298 | — |
| Site Ref # / Investigator 3567 | Rancho Mirage | California | 92270 | — |
| Site Ref # / Investigator 3512 | Gurnee | Illinois | 60031 | — |
| Site Ref # / Investigator 3565 | Hackensack | New Jersey | 07601 | — |
| Site Ref # / Investigator 3569 | Buffalo | New York | 14215 | — |
| Site Ref # / Investigator 3511 | Cleveland | Ohio | 44195 | — |
| Site Ref # / Investigator 5237 | Ravenna | Ohio | 44266 | — |
| Site Ref # / Investigator 3551 | Crossville | Tennessee | 38555 | — |
| Site Ref # / Investigator 3549 | Knoxville | Tennessee | 37920 | — |
| Site Ref # / Investigator 3571 | Nashville | Tennessee | 37232-6307 | — |
| Site Ref # / Investigator 3510 | Weston | Wisconsin | 54476 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00354562, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2011 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00354562 live on ClinicalTrials.gov.